Navigation Links
NSAIDs Might Lower Breast Cancer Risk
Date:10/9/2008

Analysis of 38 studies found painkillers showed protective effect

THURSDAY, Oct. 9 (HealthDay News) -- Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with a reduced risk for breast cancer, a new review suggests.

But the findings aren't an invitation for all women to start popping the popular painkillers, the researchers added.

"We don't want that to happen here, for people to jump on the bandwagon and start taking aspirin or ibuprofen," said study senior author Mahyar Etminan, an assistant professor of medicine at the University of British Columbia. "A lot of people are taking these drugs for aches and pains, and aspirin to prevent cardiac events. Those people may actually get an added benefit, but, for someone relatively healthy, we don't recommend starting to [reduce breast cancer risk] as of yet."

"From a practitioner's standpoint, it's kind of reassuring to patients if they do take NSAIDs for whatever reason," added Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "I don't think women should be taking these medicines for prevention, but if they are taking them for other reasons like heart prevention or arthritis, this should be reassuring."

The study is in the Oct. 15 issue of the Journal of the National Cancer Institute.

Use of NSAIDs has been linked to a lower risk of cancer overall, particularly colon cancer, and even to a lower risk of breast cancer, although studies looking specifically at breast cancer have produced inconsistent results.

With colleagues at the University of Santiago de Compostela in Spain, Etminan reviewed mostly observational studies which, together, involved a total of almost 3 million women.

The analysis included the group of NSAIDs known as cox-2 inhibitors, only one of which, Celebrex (celecoxib), is still on the market.

NSAID use across all participants in all studies was associated with a 12 percent lower risk of developing breast cancer. Aspirin was associated with a 13 percent reduced risk, and ibuprofen with a 21 percent reduced risk.

Different doses did not yield different results.

The authors acknowledged that, given that almost all of the studies reviewed were observational, this analysis may be subject to the certain limitations, and all such analyses are only as good as the studies they review.

On the other hand, the review was a large one and has biological plausibility. The inhibition of the enzyme cyclooxygenase (COX) is thought to be one of the ways NSAIDs might reduce cancer risk. And, according to an accompanying editorial, cox-2 is over expressed by 40 percent in invasive breast cancer and 80 percent in colorectal cancer.

At the very least, the results should prompt further research.

"The question is, how can you apply these results? These drugs are widely used but not without side effects. You're not going to put someone on ibuprofen long-term, because it's not going to help the stomach, and there are kidney effects," said Dr. Debra Monticciolo, a professor of radiology at Texas A&M Health Science Center and vice chair of research in the radiology department and chief of breast imaging at Scott & White Hospital. "This is preliminary. You're looking at an observational meta-analysis. It's not the strength of a randomized, controlled trial. You want long-term efficacy and long-term safety data. We need more information."

A randomized trial looking at the protective effect of Celebrex on breast cancer is due to be completed in 2009, Etminan said.

More information

The American Cancer Society has more on breast cancer.



SOURCES: Mahyar Etminan, Pharm.D., assistant professor, medicine, University of British Columbia; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Debra Monticciolo, M.D., professor, radiology, Texas A&M Health Science Center, and vice chair, research, radiology department, and chief, breast imaging, Scott & White Hospital; Oct. 15, 2008, Journal of the National Cancer Institute


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
2. NSAIDs No Better for Low Back Pain
3. NSAIDs Protect Against Parkinsons Disease
4. Link Uncovered Between Benign Prostatic Hyperplasia and NSAIDs, Says Harvard Mens Health Watch
5. Using coxibs and NSAIDs to treat osteoarthritis
6. Spoonful of Sugar Really Might Help Medicine Go Down
7. HIV Drug Might Spur Resistant Strains of Virus
8. Exercise Might Slow Brain Shrinkage in Alzheimers Patients
9. When it comes to putting, Tiger and Nicklaus might not have best advice
10. Popular Tilapia Might Not Help Heart
11. Vaginal Microbicides Might Help More Men Than Women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NSAIDs Might Lower Breast Cancer Risk
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... named one of Michigan’s 2017 Best and Brightest in Wellness® by Best and ... Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
Breaking Medicine Technology: